How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,005 results for

Androgenic Alopecia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. What do urologists think patients need to know when starting on androgen deprivation therapy? The perspective from Canada versus countries with lower gross domestic product Full Text available with Trip Pro

patients about: osteoporosis, loss of muscle mass, weight gain, fatigue/sleep disturbance, relationship changes, cognitive changes, and loss of body hair. Infertility was the only side effect more often disclosed by urologists in low GDP counties. Recommended management strategies for hot flashes are more likely to be pharmaceutical in Canada, and behavioral in low GDP countries. Management strategies for gynecomastia are emphasized more in low GDP countries. Physical exercise is endorsed consistently (...) What do urologists think patients need to know when starting on androgen deprivation therapy? The perspective from Canada versus countries with lower gross domestic product Androgen deprivation therapy (ADT) side effects are numerous and negatively impact prostate cancer patients' quality of life. There is considerable discrepancy though among Canadian urologists regarding what ADT side effects and side effect management strategies. Little is known about global differences in ADT patient

2016 Translational andrology and urology

142. Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

) and HER2 negative breast cancer by IHC and /or fluorescence in situ hybridization (FISH) Androgen receptor positive (AR+) Defined as >= 50% nuclear AR staining by immunohistochemistry (IHC) in either the primary or metastatic lesion NOTE: Research testing of AR status is available at City of Hope Pathology Resolution of grade 2 and above toxicities of most recent therapy except for stable sensory neuropathy (=< grade 2) and alopecia Female (childbearing potential): use an adequate method of birth (...) Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2016 Clinical Trials

143. The Androgen Receptor Antagonizes Wnt/β-Catenin Signaling in Epidermal Stem Cells. Full Text available with Trip Pro

The Androgen Receptor Antagonizes Wnt/β-Catenin Signaling in Epidermal Stem Cells. Activation of Wnt/β-catenin signaling in adult mouse epidermis leads to expansion of the stem cell compartment and redirects keratinocytes in the interfollicular epidermis and sebaceous glands (SGs) to differentiate along the hair follicle (HF) lineages. Here we demonstrate that during epidermal development and homeostasis there is reciprocal activation of the androgen receptor (AR) and β-catenin in cells (...) of the HF bulb. AR activation reduced β-catenin-dependent transcription, blocked β-catenin-induced induction of HF growth, and prevented β-catenin-mediated conversion of SGs into HFs. Conversely, AR inhibition enhanced the effects of β-catenin activation, promoting HF proliferation and differentiation, culminating in the formation of benign HF tumors and a complete loss of SG identity. We conclude that AR signaling has a key role in epidermal stem cell fate selection by modulating responses to β-catenin

2015 Journal of Investigative Dermatology

144. Assessment of the usefulness of dihydrotestosterone in the diagnostics of patients with androgenetic alopecia Full Text available with Trip Pro

Assessment of the usefulness of dihydrotestosterone in the diagnostics of patients with androgenetic alopecia Androgenetic alopecia (AGA) is the most common form of hair loss. Clinically observed hair loss is due to the continuous miniaturization of affected hair follicles. Genetic factors and androgenic factors especially dihydrotestosterone (DHT), which is a testosterone tissue metabolite, play major roles in the pathogenesis of AGA. However, expert opinions about the usefulness of DHT (...) in the diagnosis of this type of alopecia are divided.To evaluate the usefulness of DHT level in patients with androgenetic alopecia compared with the control group.The study comprised 49 subjects: 19 women and 9 men with androgenetic alopecia. The control group consisted of 17 healthy women and 4 men without hair loss.Increased serum concentrations of DHT were observed in patients with androgenetic alopecia (17 women, 5 men), but also in the control group. The differences in mean values of DHT were

2014 Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii

145. A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males

to 60 Years (Adult) Sexes Eligible for Study: Male Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Male with a diagnosis of Androgenetic Alopecia according to the Guidelines of the American Academy of Dermatology Experiencing active hair loss within the last 12 months. In general good health Norwood-Hamilton classification of 3, 3A, 3V, 4, 4A, or 5 Skin Type I, II, III or IV on the Fitzpatrick Skin Type Scale Between 20 and 60 years of age at the time of enrollment Willing to have a dot (...) of this protocol is to demonstrate that the intended users of the X5 HairLaser can safely and effectively perform self-use application by following written instructions. Condition or disease Intervention/treatment Phase Androgenetic Alopecia Device: X5 HairLaser Device: X5 Hair Laser Sham Device Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Intervention Model: Parallel Assignment Primary Purpose: Treatment Official Title: A Randomized, Double

2014 Clinical Trials

146. Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia

. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult) Sexes Eligible for Study: Male Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Men between the ages 18-65. Disease Stage: Norwood Hamilton IIIa-IV. Length of time with disease < 10 years. Exclusion Criteria: Must not have other concurrent hair disease. Have not used any oral anti androgen (Finasteride or Dutasteride) in the past six months. If so, a washout (...) for additonal information Responsible Party: Jerry Shapiro, Clinical Professor, Vancouver General Hospital ClinicalTrials.gov Identifier: Other Study ID Numbers: H13-03501 First Posted: June 3, 2014 Last Update Posted: June 3, 2014 Last Verified: May 2014 Additional relevant MeSH terms: Layout table for MeSH terms Alopecia Alopecia Areata Hypotrichosis Hair Diseases Skin Diseases Pathological Conditions, Anatomical Minoxidil Antihypertensive Agents Vasodilator Agents

2014 Clinical Trials

147. A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)

products will be allowed (e.g., hair gel, mousse, styling spray). Willing to use a mild non-medicated shampoo and conditioner for the duration of the study Willing to receive a small scalp tattoo Able to read and understand English Exclusion Criteria: Clinical diagnosis of alopecia areata or other non-AGA forms of alopecia Scalp hair loss on the treatment area, due to disease, injury, or medical therapy Males who are sexually active and have a partner who is capable of becoming pregnant, neither (...) , might put the subject at risk or interfere with the study conduct or evaluations History of surgical correction of hair loss on the scalp Previous exposure to SM04554 Use of any products or devices purported to promote scalp hair growth (e.g., finasteride or minoxidil) within the 24 weeks prior to study start Use of anti-androgenic therapies (e.g., spironolactone, flutamide, cyproterone acetate, cimetidine) within 12 weeks prior to study start History of hair transplants Current use of an occlusive

2014 Clinical Trials

148. Minoxidil Response Testing in Males With Androgenetic Alopecia

.: alopecia androgenetic alopecia hair loss minoxidil 5% minoxidil foam male pattern hair loss Additional relevant MeSH terms: Layout table for MeSH terms Alopecia Alopecia Areata Hypotrichosis Hair Diseases Skin Diseases Pathological Conditions, Anatomical Minoxidil Antihypertensive Agents Vasodilator Agents (...) : 18 Years to 49 Years (Adult) Sexes Eligible for Study: Male Accepts Healthy Volunteers: No Sampling Method: Non-Probability Sample Study Population Males with androgenetic alopecia Criteria Inclusion Criteria: Males in overall good health Age: 18 to 49 Diagnosed with male androgenetic alopecia with vertex pattern IIIv, IV, or V on the Norwood Hamilton Scale Willing to have a mini dot tattoo placed in the target area of the scalp Willing to maintain the same hair style, color, shampoo and hair

2014 Clinical Trials

149. A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia

Andrasfay Therapeutics, Inc. More Information Go to Layout table for additonal information Responsible Party: Intrepid Therapeutics, Inc. ClinicalTrials.gov Identifier: Other Study ID Numbers: 171-7152-201 First Posted: October 31, 2014 Last Update Posted: March 13, 2017 Last Verified: March 2017 Keywords provided by Intrepid Therapeutics, Inc.: androgen alopecia CB-03-01 solution topical Additional relevant MeSH terms: Layout table for MeSH terms Alopecia Alopecia Areata Hypotrichosis Hair Diseases (...) information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 50 Years (Adult) Sexes Eligible for Study: Male Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Subject has mild to moderate androgenetic alopecia (AGA) in temple and vertex region Subject is willing to maintain the same hairstyle, hair length, and hair color throughout the study Subject agrees to continue his other general hair care products and regimen for the entire study Subjects who are sexually

2014 Clinical Trials

150. Insulin-Like Growth Factor -1: Roles In Androgenetic Alopecia. (Abstract)

Insulin-Like Growth Factor -1: Roles In Androgenetic Alopecia. Of all the cytokines or growth factors that have been postulated to play a role in hair follicle, insulin-like growth factor-1 (IGF-1) is known to be regulated by androgens. However, how IGF-1 is altered in the balding scalp has not yet been investigated. In this study, expressions of IGF-1 and its binding proteins by dermal papilla (DP) cells obtained from balding versus non-balding hair follicles were quantified using growth (...) factor array. DP cells from balding scalp follicles were found to secrete significantly less IGF-1, IGFBP-2 and IGFBP-4 (P < 0.05) than their non-balding counterparts. Our data confirmed that the downregulation of IGF-1 may be one of the important mechanisms contributing to male pattern baldness.© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

2014 Experimental Dermatology

151. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. (Abstract)

A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. Dihydrotestosterone is the main androgen causative of androgenetic alopecia, a psychologically and physically harmful condition warranting medical treatment.We sought to compare the efficacy and safety of dutasteride (type 1 and 2 5-alpha reductase inhibitor) with finasteride (type 2 5-alpha (...) reductase inhibitor) and placebo in men with androgenetic alopecia.Men aged 20 to 50 years with androgenetic alopecia were randomized to receive dutasteride (0.02, 0.1, or 0.5 mg/d), finasteride (1 mg/d), or placebo for 24 weeks. The primary end point was hair count (2.54-cm diameter) at week 24. Other assessments included hair count (1.13-cm diameter) and width, photographic assessments (investigators and panel), change in stage, and health outcomes.In total, 917 men were randomized. Hair count

2014 Journal of the American Academy of Dermatology Controlled trial quality: uncertain

152. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. (Abstract)

Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. Hair loss may significantly impact an individual's self-image, and studies indicate that patients with both clinically apparent and clinically imperceptible hair loss may have significantly decreased quality of life (QoL). Moreover, clinical severity of hair loss does not necessarily predict impact on QoL.The aim of this study was to assess QoL in patients (n (...)  = 104) with alopecia areata, telogen effluvium, and androgenic alopecia, and to compare QoL with hair loss severity (HLS) as independently rated by both patient and dermatologist.Questionnaires and clinical assessment tools were used to assess HLS, and QoL was measured by completion of Skindex-16.Overall, patients rated their hair loss as more severe than the dermatologist, and the patient's HLS rating more strongly correlated with QoL than the dermatologist's rating. Clinical assessment of HLS did

2011 Journal of American Academy of Dermatology

153. Traction Alopecia (Diagnosis)

loss of follicular ostia, or atrophy. Clinical inflammation is frequently, but not always, present. Histologic inflammation may be present. Ultimately, histologic confirmation is the best method to confirm the presence of a fibrosing/scarring process with loss of hair follicles. Many alopecia types are biphasic. For example, androgenetic alopecia eventually results in loss of ostia and thus may appear like a scarring alopecia. This article focuses on the alopecia types that are believed to be due (...) be permanently destroyed. Note the image below. Alopecia due to primary cutaneous follicular center cell lymphoma. Used with permission, rights retained, courtesy of Rashid M. Rashid, MD, PhD, Morzak Research Collaborative. Alopecia mucinosa Follicular mucinosis can exist by itself or can be a manifestation of mycosis fungoides. Keratosis pilaris atrophicans Keratosis pilaris atrophicans involves a spectrum of conditions that resemble keratosis pilaris, but result in hair loss. Diagnoses in which neutrophils

2014 eMedicine.com

154. Androgenetic Alopecia (Treatment)

. The role of inflammation and immunity in the pathogenesis of androgenetic alopecia. J Drugs Dermatol . 2011 Dec. 10(12):1404-11. . Brockschmidt FF, Heilmann S, Ellis JA, et al. Susceptibility variants on chromosome 7p21.1 suggest HDAC9 as a new candidate gene for male-pattern baldness. Br J Dermatol . 2011 Dec. 165(6):1293-302. . Kure K, Isago T, Hirayama T. Changes in the sebaceous gland in patients with male pattern hair loss (androgenic alopecia). J Cosmet Dermatol . 2015 Sep. 14 (3):178-84. . Kaya (...) . Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol . 1977 Sep. 97(3):247-54. . Hillmer AM, Flaquer A, Hanneken S, et al. Genome-wide scan and fine-mapping linkage study of androgenetic alopecia reveals a locus on chromosome 3q26. Am J Hum Genet . 2008 Mar. 82(3):737-43. . . Alsantali A, Shapiro J. Androgens and hair loss. Curr Opin Endocrinol Diabetes Obes . 2009 Jun. 16(3):246-53. . Krajcik RA, Vogelman JH, Malloy VL, Orentreich N. Transplants

2014 eMedicine.com

155. Traction Alopecia (Treatment)

and chemical hair straightening Use of tight curlers and nylon brushes Wearing the hair in a chignon (bun) Previous References Chiu HY, Lin SJ. Fibrosing alopecia in a pattern distribution. J Eur Acad Dermatol Venereol . 2010 Feb 2. . Olsen EA. Female pattern hair loss and its relationship to permanent/cicatricial alopecia: a new perspective. J Investig Dermatol Symp Proc . 2005 Dec. 10(3):217-21. . Ross EK, Tan E, Shapiro J. Update on primary cicatricial alopecias. J Am Acad Dermatol . 2005 Jul. 53(1):1 (...) . Break dancing: a new risk factor for scarring hair loss. J Cutan Med Surg . 2011 May-Jun. 15(3):177-9. . Whiting DA. Cicatricial alopecia: clinico-pathological findings and treatment. Clin Dermatol . 2001 Mar-Apr. 19(2):211-25. . Khumalo NP, Jessop S, Gumedze F, Ehrlich R. Determinants of marginal traction alopecia in African girls and women. J Am Acad Dermatol . 2008 Sep. 59(3):432-8. . Ochoa BE, King LE Jr, Price VH. Lichen planopilaris: Annual incidence in four hair referral centers in the United

2014 eMedicine.com

156. Traction Alopecia (Overview)

loss of follicular ostia, or atrophy. Clinical inflammation is frequently, but not always, present. Histologic inflammation may be present. Ultimately, histologic confirmation is the best method to confirm the presence of a fibrosing/scarring process with loss of hair follicles. Many alopecia types are biphasic. For example, androgenetic alopecia eventually results in loss of ostia and thus may appear like a scarring alopecia. This article focuses on the alopecia types that are believed to be due (...) be permanently destroyed. Note the image below. Alopecia due to primary cutaneous follicular center cell lymphoma. Used with permission, rights retained, courtesy of Rashid M. Rashid, MD, PhD, Morzak Research Collaborative. Alopecia mucinosa Follicular mucinosis can exist by itself or can be a manifestation of mycosis fungoides. Keratosis pilaris atrophicans Keratosis pilaris atrophicans involves a spectrum of conditions that resemble keratosis pilaris, but result in hair loss. Diagnoses in which neutrophils

2014 eMedicine.com

157. Androgenetic Alopecia (Overview)

Dermatol . 2011 Dec. 10(12):1404-11. . Brockschmidt FF, Heilmann S, Ellis JA, et al. Susceptibility variants on chromosome 7p21.1 suggest HDAC9 as a new candidate gene for male-pattern baldness. Br J Dermatol . 2011 Dec. 165(6):1293-302. . Kure K, Isago T, Hirayama T. Changes in the sebaceous gland in patients with male pattern hair loss (androgenic alopecia). J Cosmet Dermatol . 2015 Sep. 14 (3):178-84. . Kaya Erdogan H, Bulur I, Kocaturk E, Yildiz B, Saracoglu ZN, Alatas O. The role of oxidative (...) in the female sex. Br J Dermatol . 1977 Sep. 97(3):247-54. . Hillmer AM, Flaquer A, Hanneken S, et al. Genome-wide scan and fine-mapping linkage study of androgenetic alopecia reveals a locus on chromosome 3q26. Am J Hum Genet . 2008 Mar. 82(3):737-43. . . Alsantali A, Shapiro J. Androgens and hair loss. Curr Opin Endocrinol Diabetes Obes . 2009 Jun. 16(3):246-53. . Krajcik RA, Vogelman JH, Malloy VL, Orentreich N. Transplants from balding and hairy androgenetic alopecia scalp regrow hair comparably well

2014 eMedicine.com

158. Traction Alopecia (Follow-up)

and chemical hair straightening Use of tight curlers and nylon brushes Wearing the hair in a chignon (bun) Previous References Chiu HY, Lin SJ. Fibrosing alopecia in a pattern distribution. J Eur Acad Dermatol Venereol . 2010 Feb 2. . Olsen EA. Female pattern hair loss and its relationship to permanent/cicatricial alopecia: a new perspective. J Investig Dermatol Symp Proc . 2005 Dec. 10(3):217-21. . Ross EK, Tan E, Shapiro J. Update on primary cicatricial alopecias. J Am Acad Dermatol . 2005 Jul. 53(1):1 (...) . Break dancing: a new risk factor for scarring hair loss. J Cutan Med Surg . 2011 May-Jun. 15(3):177-9. . Whiting DA. Cicatricial alopecia: clinico-pathological findings and treatment. Clin Dermatol . 2001 Mar-Apr. 19(2):211-25. . Khumalo NP, Jessop S, Gumedze F, Ehrlich R. Determinants of marginal traction alopecia in African girls and women. J Am Acad Dermatol . 2008 Sep. 59(3):432-8. . Ochoa BE, King LE Jr, Price VH. Lichen planopilaris: Annual incidence in four hair referral centers in the United

2014 eMedicine.com

159. Androgenetic Alopecia (Follow-up)

. The role of inflammation and immunity in the pathogenesis of androgenetic alopecia. J Drugs Dermatol . 2011 Dec. 10(12):1404-11. . Brockschmidt FF, Heilmann S, Ellis JA, et al. Susceptibility variants on chromosome 7p21.1 suggest HDAC9 as a new candidate gene for male-pattern baldness. Br J Dermatol . 2011 Dec. 165(6):1293-302. . Kure K, Isago T, Hirayama T. Changes in the sebaceous gland in patients with male pattern hair loss (androgenic alopecia). J Cosmet Dermatol . 2015 Sep. 14 (3):178-84. . Kaya (...) . Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol . 1977 Sep. 97(3):247-54. . Hillmer AM, Flaquer A, Hanneken S, et al. Genome-wide scan and fine-mapping linkage study of androgenetic alopecia reveals a locus on chromosome 3q26. Am J Hum Genet . 2008 Mar. 82(3):737-43. . . Alsantali A, Shapiro J. Androgens and hair loss. Curr Opin Endocrinol Diabetes Obes . 2009 Jun. 16(3):246-53. . Krajcik RA, Vogelman JH, Malloy VL, Orentreich N. Transplants

2014 eMedicine.com

160. Androgenetic Alopecia (Diagnosis)

Dermatol . 2011 Dec. 10(12):1404-11. . Brockschmidt FF, Heilmann S, Ellis JA, et al. Susceptibility variants on chromosome 7p21.1 suggest HDAC9 as a new candidate gene for male-pattern baldness. Br J Dermatol . 2011 Dec. 165(6):1293-302. . Kure K, Isago T, Hirayama T. Changes in the sebaceous gland in patients with male pattern hair loss (androgenic alopecia). J Cosmet Dermatol . 2015 Sep. 14 (3):178-84. . Kaya Erdogan H, Bulur I, Kocaturk E, Yildiz B, Saracoglu ZN, Alatas O. The role of oxidative (...) in the female sex. Br J Dermatol . 1977 Sep. 97(3):247-54. . Hillmer AM, Flaquer A, Hanneken S, et al. Genome-wide scan and fine-mapping linkage study of androgenetic alopecia reveals a locus on chromosome 3q26. Am J Hum Genet . 2008 Mar. 82(3):737-43. . . Alsantali A, Shapiro J. Androgens and hair loss. Curr Opin Endocrinol Diabetes Obes . 2009 Jun. 16(3):246-53. . Krajcik RA, Vogelman JH, Malloy VL, Orentreich N. Transplants from balding and hairy androgenetic alopecia scalp regrow hair comparably well

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>